NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
16 May 2024
| Name: | BOD SCIENCE LIMITED (BOD) | |||||||||
| ISIN: | AU0000181331 | |||||||||
| Date of Listing: | 27 October 2016 | |||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently suspended from quotation on the Australian Securities Exchange and its securities cannot be traded on-market.Legal Status: (updated monthly)
ACN: 601 225 441ABN: 89 601 225 441
Registration Date: 13 August 2014
Capital Gains Tax (CGT) Status: (updated at least quarterly)
The securities in this entity, in our opinion, are of little or no value. We have made that assessment by reference to the circumstances leading to a suspension and/or delisting, the length of a suspension, share trading history and last on-market share price, most recent financial and cash flow statements, prospects (including likelihood of re-financing), and other factors including in particular whether the entity is in external administration. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| BOD SCIENCE LIMITED | 30/12/2022 | |
| BOD AUSTRALIA LIMITED | 18/10/2021 | 30/12/2022 |
| BOD AUSTRALIA LIMITED | 18/10/2021 |
Link Market Services Limited Sydney
Level 12, 680 George Street
Sydney NSW 2000
Tel : +61 1300 361 735
Fax : 02 9287 0303
RegistryWebsite RegistryEmail
Expand this box to read and print
The Appendix 4D and Half-Year Report that was supposed to be lodged by 30th April 2024 is still ongoing and the Company now expects that the half-year review will be lodged by 24th May 2024. | 29/04/2024 |
The Deed Administrator of the company announce that on 8 April 2024, creditors of BOD resolved to accept a Deed of Company Arrangement as proposed by Biortica Agrimed Limited. The DOCA was executed on 24 April 2024. | 26/04/2024 |
The company releases the quarterly activities report. | 24/04/2024 |
The Administrators have today issued their report to creditors and their notice to convene the second meeting of creditors which will be held on 8 April 2024. | 28/03/2024 |
The Company was advised by ASIC on 22nd March 2024 that it had rejected the application of Bod's incumbent auditor, Nexia Sydney Audit Pty Ltd, to resign as the Company's auditor due to a perceived conflict of interest. Due to delays in receiving the ASIC decision, the Company's half-year review by Nexia Sydney Audit Pty Ltd has not yet commenced and the Company will not meet the previously advised expected lodgement date of 28th March 2024. The Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 30th April 2024. | 25/03/2024 |
The Company was advised by ASIC on 22nd March 2024 that it had rejected the application of Bod's incumbent auditor, Nexia Sydney Audit Pty Ltd, to resign as the Company's auditor due to a perceived conflict of interest. Due to delays in receiving the ASIC decision, the Company's half-year review by Nexia Sydney Audit Pty Ltd has not yet commenced and the Company will not meet the previously advised expected lodgement date of 28th March 2024. The Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 30th April 2024. | 25/03/2024 |
The Company's Appendix 4D and Half Year Report for the half-year ended 31st December 2023 will not be lodged by today's deadline. On 20th February 2024, Bod's auditor, Nexia Sydney Audit Pty Ltd, lodged an application with ASIC to resign as the Company's auditor due to a perceived conflict of interest. In.Corp Audit & Assurance Pty Ltd has advised the Company that it is prepared to accept the appointment as auditor to Bod and on 20th February 2024, In.Corp Audit & Assurance Pty Ltd was appointed as the Company's auditor, subject to the consent of ASIC. The Company, former auditor and new auditor are awaiting upon ASIC approval before the review for the half-year ended 31st December 2023 can commence. The ASIC form 342 was lodged with ASIC on 21st February 2024 and a response is expected within two to three weeks of that date. It is expected that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 28th March 2024, dependent upon receiving ASIC consent within the expected timeframe. | 29/02/2024 |
The company releases a notification of cessation of securities. | 08/02/2024 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 30/01/2024 |
The Administrators of BOD Science Limited announce that on 14 December 2023, the Federal Court of Australia granted an extension of the period by which the Administrators must convene the second meeting of creditors to no later than 29 March 2024. | 15/12/2023 |
Supply agreement with licenced cultivator, importer and genetic holder of medicinal cannabis, Green Farmers Pty Ltd (Licence Number MC022/18v3) (Green Farmers). Green Farmers is a leading Australian grower of medicinal cannabis, with a cropping facility (glasshouse) of 4,000 sqm of cultivation area. | 13/12/2023 |
The Company releases a letter to its shareholders regarding the appointment of Administrators. The appointment was made by the Company's directors, who took the step to appoint the Voluntary Administrators to enable them, as experienced and independent parties, to assess the Company's options as to how to secure and sustain the future viability of the business. The Voluntary Administrators are presently considering opportunities to obtain funding from interested parties and/or sell the business. In the meantime, it is business as usual, as far as possible, for the Company in the short term. | 01/12/2023 |
On 29 November 2023, the Board of Directors of Bod Science Limited the Board of Directors of Bod Science Limited of Rodgers Reidy as Joint and Several Administrators of the Company pursuant to section 436A of the Corporations Act 2001. | 29/11/2023 |
The securities of BOD Science Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BOD, pending the release of an announcement regarding a potential corporate transaction critical to its continued financial viability. | 28/11/2023 |
The suspension of trading in the securities of BOD Science Limited will be lifted immediately following the release by BOD of an announcement regarding its capital raising. | 08/11/2023 |
Bod Science has received firm commitments to raise a total of A$2.05 million under a two-tranche placement at an offer price of $0.03 per share. Bod's partner for Malaysia, Antah Healthcare, cornered the raising and will emerge as a 14.9% shareholder. Proceeds will be utilised to fund to fund inventory build, product manufacture, R&D activity to support Aqua Phase and working capital. Post transaction the Company's pro forma cash balance (as at 30 September 2023) will be $2.165m. Cash management initiatives including reduced executive salaries and director fees to be taken in shares (subject to shareholder approval). | 08/11/2023 |
The extension to the voluntary suspension is required to enable the Company to finalise its capital raising in an orderly manner. The Company expects the voluntary suspension to last for an additional two trading days. The Company requests that the voluntary suspension remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the capital raising and the commencement of trading on Wednesday, 8 November 2023. | 06/11/2023 |
The securities of BOD Science Limited were suspended from quotation under Listing Rule 17.5 on Wednesday, 1 November 2023 as BOD did not lodge its Full Year Statutory Accounts by the due date. BOD has since lodged its Full Year Statutory Accounts, however BOD will continue to be suspended from quotation under Listing Rule 17.2, at the request of BOD, pending the release of an announcement regarding its capital raising. | 02/11/2023 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Wednesday, 1 November 2023, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Tuesday, 31 October 2023, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/11/2023 |
name changed from Bod Australia Limited | 30/12/2022 |
The Appendix 4D and Half-Year Report that was supposed to be lodged by 30th April 2024 is still ongoing and the Company now expects that the half-year review will be lodged by 24th May 2024. | 29/04/2024 |
The Deed Administrator of the company announce that on 8 April 2024, creditors of BOD resolved to accept a Deed of Company Arrangement as proposed by Biortica Agrimed Limited. The DOCA was executed on 24 April 2024. | 26/04/2024 |
The company releases the quarterly activities report. | 24/04/2024 |
The Administrators have today issued their report to creditors and their notice to convene the second meeting of creditors which will be held on 8 April 2024. | 28/03/2024 |
The Company was advised by ASIC on 22nd March 2024 that it had rejected the application of Bod's incumbent auditor, Nexia Sydney Audit Pty Ltd, to resign as the Company's auditor due to a perceived conflict of interest. Due to delays in receiving the ASIC decision, the Company's half-year review by Nexia Sydney Audit Pty Ltd has not yet commenced and the Company will not meet the previously advised expected lodgement date of 28th March 2024. The Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 30th April 2024. | 25/03/2024 |
The Company was advised by ASIC on 22nd March 2024 that it had rejected the application of Bod's incumbent auditor, Nexia Sydney Audit Pty Ltd, to resign as the Company's auditor due to a perceived conflict of interest. Due to delays in receiving the ASIC decision, the Company's half-year review by Nexia Sydney Audit Pty Ltd has not yet commenced and the Company will not meet the previously advised expected lodgement date of 28th March 2024. The Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 30th April 2024. | 25/03/2024 |
The Company's Appendix 4D and Half Year Report for the half-year ended 31st December 2023 will not be lodged by today's deadline. On 20th February 2024, Bod's auditor, Nexia Sydney Audit Pty Ltd, lodged an application with ASIC to resign as the Company's auditor due to a perceived conflict of interest. In.Corp Audit & Assurance Pty Ltd has advised the Company that it is prepared to accept the appointment as auditor to Bod and on 20th February 2024, In.Corp Audit & Assurance Pty Ltd was appointed as the Company's auditor, subject to the consent of ASIC. The Company, former auditor and new auditor are awaiting upon ASIC approval before the review for the half-year ended 31st December 2023 can commence. The ASIC form 342 was lodged with ASIC on 21st February 2024 and a response is expected within two to three weeks of that date. It is expected that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 28th March 2024, dependent upon receiving ASIC consent within the expected timeframe. | 29/02/2024 |
The company releases a notification of cessation of securities. | 08/02/2024 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 30/01/2024 |
The Administrators of BOD Science Limited announce that on 14 December 2023, the Federal Court of Australia granted an extension of the period by which the Administrators must convene the second meeting of creditors to no later than 29 March 2024. | 15/12/2023 |
Supply agreement with licenced cultivator, importer and genetic holder of medicinal cannabis, Green Farmers Pty Ltd (Licence Number MC022/18v3) (Green Farmers). Green Farmers is a leading Australian grower of medicinal cannabis, with a cropping facility (glasshouse) of 4,000 sqm of cultivation area. | 13/12/2023 |
The Company releases a letter to its shareholders regarding the appointment of Administrators. The appointment was made by the Company's directors, who took the step to appoint the Voluntary Administrators to enable them, as experienced and independent parties, to assess the Company's options as to how to secure and sustain the future viability of the business. The Voluntary Administrators are presently considering opportunities to obtain funding from interested parties and/or sell the business. In the meantime, it is business as usual, as far as possible, for the Company in the short term. | 01/12/2023 |
On 29 November 2023, the Board of Directors of Bod Science Limited the Board of Directors of Bod Science Limited of Rodgers Reidy as Joint and Several Administrators of the Company pursuant to section 436A of the Corporations Act 2001. | 29/11/2023 |
The securities of BOD Science Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BOD, pending the release of an announcement regarding a potential corporate transaction critical to its continued financial viability. | 28/11/2023 |
The suspension of trading in the securities of BOD Science Limited will be lifted immediately following the release by BOD of an announcement regarding its capital raising. | 08/11/2023 |
Bod Science has received firm commitments to raise a total of A$2.05 million under a two-tranche placement at an offer price of $0.03 per share. Bod's partner for Malaysia, Antah Healthcare, cornered the raising and will emerge as a 14.9% shareholder. Proceeds will be utilised to fund to fund inventory build, product manufacture, R&D activity to support Aqua Phase and working capital. Post transaction the Company's pro forma cash balance (as at 30 September 2023) will be $2.165m. Cash management initiatives including reduced executive salaries and director fees to be taken in shares (subject to shareholder approval). | 08/11/2023 |
The extension to the voluntary suspension is required to enable the Company to finalise its capital raising in an orderly manner. The Company expects the voluntary suspension to last for an additional two trading days. The Company requests that the voluntary suspension remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the capital raising and the commencement of trading on Wednesday, 8 November 2023. | 06/11/2023 |
The securities of BOD Science Limited were suspended from quotation under Listing Rule 17.5 on Wednesday, 1 November 2023 as BOD did not lodge its Full Year Statutory Accounts by the due date. BOD has since lodged its Full Year Statutory Accounts, however BOD will continue to be suspended from quotation under Listing Rule 17.2, at the request of BOD, pending the release of an announcement regarding its capital raising. | 02/11/2023 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Wednesday, 1 November 2023, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Tuesday, 31 October 2023, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/11/2023 |
name changed from Bod Australia Limited | 30/12/2022 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 09/03/2023 | David Baker | 764,705 | $0.063 | $47,794 |
| 16/10/2020 | George Livery | -20,202 | $0.545 | $11,010 |
| 20/11/2019 | Mark Masterson | 441,176 | $0.340 | $150,000 |
| 04/11/2019 | George Livery | 20,202 | $0.370 | $7,475 |
| 16/01/2019 | Joanne Patterson | 100,000 | $0.500 | $50,000 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| David Baker | Non Exec Chairman | 04/04/2022 |
| Adrian Sturrock | CFO | 02/08/2021 |
| Akash Bedi | Non Exec Director | 23/07/2019 |
| George Livery | Non Exec Director | 01/09/2018 |
| Joanne Patterson | Director, CEO | 27/10/2016 |
| Carlie Hodges | Company Secretary |
Date of first appointment, title may have changed.
SPECIAL NOTE: During May 2024 we are working to remove duplications in the Company Secretary role.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Hanno Cappon | Non Exec Director | 21/07/2021 | 09/11/2022 |
| Mark Masterson | Non Exec Chairman | 11/11/2019 | 16/05/2022 |
| Simon O'Loughlin | Non Exec Director | 27/10/2016 | 04/04/2022 |
| Alan Dworkin | CFO | 03/05/2021 | 02/08/2021 |
| Patrice Malard | Non Exec Director | 23/07/2019 | 21/07/2021 |
| Charles Altshuler | CFO | 19/02/2019 | 31/03/2021 |
| Stephen Thompson | Alternate Director | 01/09/2018 | 18/12/2019 |
| Simon Taylor | Non Exec Director | 27/10/2016 | 13/11/2019 |
| Mickey Perret | Non Exec Director | 07/08/2017 | 21/01/2019 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
